{"name":"Ipsapirone","slug":"ipsapirone","kind":"substance","abbreviations":[],"systematic":null,"aliases":["Ipsapirona","Ipsapironum","Tvx-q-7821","isapirone","1,1-dioxo-2-(4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl)-1,2-benzothiazol-3-one","Tvx q 7821","Ccg-220609","Ipsapironum [Latin]","Ipsapirona [Spanish]","C19h23n5o3s"],"brands":[],"scraped":true,"has_structure":true,"cid":56971,"classes":[],"families":[{"name":"benzylamine","href":"/substituted/benzylamine"}],"physical":[{"label":"Molecular mass","value":"401.50 g/mol","copyable":false},{"label":"Predicted LogP","value":"1.5","copyable":false}],"identifiers":[{"label":"Molecular formula","value":"C<sub>19</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S","copyable":true},{"label":"IUPAC name","value":"1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one","copyable":true},{"label":"SMILES","value":"C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4","copyable":true},{"label":"InChI","value":"InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2","copyable":true},{"label":"InChIKey","value":"TZJUVVIWVWFLCD-UHFFFAOYSA-N","copyable":true},{"label":"CAS number","value":"95847-70-4","copyable":true},{"label":"UNII","value":"6J9B11MN0K","copyable":true},{"label":"PubChem CID","value":"56971","copyable":true}],"pharmacokinetics":[{"label":"Elimination half-life","value":"Ipsapirone: 1–3 hours, 1-PP: 6.1 hours<a href=\"#cite_note-3\"><sup>[3]</sup></a><a href=\"#cite_note-4\"><sup>[4]</sup></a>","copyable":false},{"label":"Routes of administration","value":"Oral","copyable":false}],"toxicity":[],"dosing":null,"salts":[{"title":"Ipsapirone hydrochloride","name":"hydrochloride","slug":"ipsapirone_hydrochloride","drawn":true}],"esters":[],"chirality":"achiral","stereo_type":null,"optical_activity":null,"stereoisomers":[],"lipinski":{"passes":true,"violations":0},"reagents":[],"atc":[],"mesh":[{"name":"Anti-Anxiety Agents","id":"M0021771"},{"name":"Serotonin Receptor Agonists","id":"M0026371"}],"actives":[],"prodrugs":[],"codrug":false,"interactions":[],"mechanism":null,"side_effects":null,"effects":null,"usernotes":[],"erowid":[],"reddit":[],"legal":[{"jurisdiction":"Other","status":"Uncontrolled","act":null,"refs":[]}],"members":[],"part_of":[],"links":[{"source":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ipsapirone"},{"source":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/56971"},{"source":"Wikidata","url":"https://www.wikidata.org/wiki/Q6065448"},{"source":"DrugBank","url":"https://go.drugbank.com/drugs/DB20133"},{"source":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL8412"},{"source":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A93578"},{"source":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=95847-70-4"},{"source":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0253573"},{"source":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4045688"},{"source":"Effect Index","url":"https://www.effectindex.com/search?q=Ipsapirone"},{"source":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6J9B11MN0K"}],"references":["National Center for Biotechnology Information. PubChem Compound Summary for CID 56971, Ipsapirone. Accessed November 21, 2026. <a href=https://pubchem.ncbi.nlm.nih.gov/compound/56971>https://pubchem.ncbi.nlm.nih.gov/compound/56971</a>","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ipsapirone. UNII: 6J9B11MN0K. Global Substance Registration System. Accessed November 21, 2026. <a href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6J9B11MN0K>https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6J9B11MN0K</a>","Fuhr U, Staib AH, Harder S, Becker K, Liermann D, Schöllnhammer G, Roed IS. Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol. July 1994; 38(1):83–86. PMID 7946942. <a href=''></a>","Berlin I, Chalon S, Payan C, Schöllnhammer G, Cesselin F, Varoquaux O, Puech AJ. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. Br J Clin Pharmacol. March 1995; 39(3):243–249. PMID 7619663. <a href=''></a>"],"sources":[{"source":"dosing","status":"missing","fetched_at":"2026-11-20 19:00:30","note":"no dosing statistics"},{"source":"drugspro","status":"missing","fetched_at":"2026-11-20 19:00:26","note":"no DrugsPRO reagent data"},{"source":"erowid","status":"missing","fetched_at":"2026-11-20 19:00:26","note":"no Erowid substance of that name"},{"source":"gsrs","status":"ok","fetched_at":"2026-11-20 19:00:27","note":null},{"source":"hmdb","status":"missing","fetched_at":"2026-11-20 19:00:26","note":"hmdb.ca refused automated access to HMDB0253573"},{"source":"kegg","status":"missing","fetched_at":"2026-11-20 19:00:29","note":"no KEGG DRUG entry"},{"source":"pubchem","status":"ok","fetched_at":"2026-11-20 19:00:26","note":null},{"source":"reddit","status":"missing","fetched_at":"2026-11-20 19:00:26","note":"no r/tripreports posts mention it"},{"source":"sider","status":"missing","fetched_at":"2026-11-20 19:00:26","note":"not in SIDER"},{"source":"structure","status":"ok","fetched_at":"2026-11-20 19:00:26","note":null},{"source":"wikipedia","status":"ok","fetched_at":"2026-11-20 19:00:26","note":null}],"description":"Ipsapirone is a  substance."}